{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:59:15Z","timestamp":1783133955325,"version":"3.54.6"},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Asthma is one of the most common chronic diseases characterized by sex disparities. Gender bias is a well-documented issue detected in the design of published clinical trials (CTs). International guidelines encourage researchers to analyze clinical data by sex, gender, or both where appropriate. The objective of this work was to evaluate gender bias in the published CTs of biological agents for the treatment of severe asthma. A systematic review of randomized controlled CTs of the biological agents (omalizumab, benralizumab, reslizumab, mepolizumab or dupilumab) for the treatment of severe asthma was conducted. The literature search was performed using PubMed and EMBASE without language restrictions. This study followed the corresponding international recommendations. We identified a total of 426 articles, of which 37 were finally included. Women represented 60.4% of patients included. The mean percentage of women in these trials was 59.9%, ranged from 40.8% to 76.7%. The separate analysis by sex of the main variable was only performed in 5 of the 37 publications included, and none of the trials analyzed secondary variables by sex. Only 1 of the articles discussed the results separately by sex. No study included the concept of gender in the text or analyzed the results separately by gender. The proportion of women included in CTs was higher compared to publications of other disciplines, where women were under-represented. The analysis of the main and secondary variables by sex or gender, even the discussion separately by sex, was insufficient. This gives rise to potential gender bias in these CTs.<\/jats:p>","DOI":"10.1371\/journal.pone.0257765","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T18:17:33Z","timestamp":1632421053000},"page":"e0257765","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Gender bias in clinical trials of biological agents for severe asthma: A systematic review"],"prefix":"10.1371","volume":"16","author":[{"given":"Pablo","family":"Ciudad-Guti\u00e9rrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-2879","authenticated-orcid":true,"given":"Beatriz","family":"Fern\u00e1ndez-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"Guisado-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"issue":"Suppl 2","key":"pone.0257765.ref001","first-page":"ii46","article-title":"A framework to analyse gender bias in epidemiological research","volume":"61","author":"MT Ruiz-Cantero","year":"2007","journal-title":"J Epidemiol Community Health"},{"key":"pone.0257765.ref002","unstructured":"Collins Dictionary; 2020 [cited 2021 Aug 10]. Available from https:\/\/www.collinsdictionary.com\/."},{"key":"pone.0257765.ref003","author":"U.S. Food and Drug Administration (FDA)","year":"1993","journal-title":"Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs"},{"key":"pone.0257765.ref004","author":"European Medicines Agency (EMA)","year":"2005","journal-title":"ICH Gender Considerations in the Conduct of Clinical Trials"},{"key":"pone.0257765.ref005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","article-title":"Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use","volume":"1","author":"S Heidari","year":"2016","journal-title":"Res Integr Peer Rev."},{"key":"pone.0257765.ref006","first-page":"109","article-title":"Gender bias in therapeutic effort: from research to health care","volume":"44","author":"MT Ruiz-Cantero","year":"2020","journal-title":"Farm Hosp"},{"issue":"3","key":"pone.0257765.ref007","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/pubmed\/fdp024","article-title":"Women\u2019s health and gender-based clinical trials on etoricoxib: methodological gender bias","volume":"31","author":"E Chilet-Rosell","year":"2009","journal-title":"J Public Health (Oxf)"},{"issue":"7","key":"pone.0257765.ref008","first-page":"552","article-title":"Effects of Gender Bias and Stereotypes in Surgical Training","volume":"155","author":"SP Myers","year":"2020","journal-title":"A Randomized Clinical Trial. JAMA Surg."},{"issue":"7","key":"pone.0257765.ref009","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/aas.12337","article-title":"Gender differences in randomised, controlled trials in intensive care units","volume":"58","author":"ML Kristensen","year":"2014","journal-title":"Acta Anaesthesiol Scand"},{"issue":"9","key":"pone.0257765.ref010","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/jwh.2009.1784","article-title":"Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression","volume":"19","author":"AH Weinberger","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"pone.0257765.ref011","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/JCP.0000000000001041","article-title":"Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs","volume":"39","author":"M Santos-Casado","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"pone.0257765.ref012","first-page":"110088","article-title":"Systematic review of gender bias in vortioxetine clinical trials","author":"M Santos-Casado","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"pone.0257765.ref013","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/13607863.2014.938601","article-title":"Psychosocial interventions in Alzheimer\u2019s disease and amnestic mild cognitive impairment: evidence for gender bias in clinical trials","volume":"19","author":"S Baron","year":"2015","journal-title":"Aging Ment Health"},{"key":"pone.0257765.ref014","first-page":"S0213-4853(21)00008-6","article-title":"Systematic review of gender bias in clinical trials of monoclonal antibodies for the treatment of multiple sclerosis","author":"M Alonso-Moreno","year":"2021","journal-title":"Neurologia (Engl Ed)"},{"issue":"6","key":"pone.0257765.ref015","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1378\/chest.119.6.1691","article-title":"Gender bias in the diagnosis of COPD","volume":"119","author":"KR Chapman","year":"2001","journal-title":"Chest"},{"key":"pone.0257765.ref016","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"A Papi","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"pone.0257765.ref017","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.3389\/fimmu.2018.02997","article-title":"Sex Bias in Asthma Prevalence and Pathogenesis","volume":"18","author":"R Shah","year":"2018","journal-title":"Front Immunol."},{"key":"pone.0257765.ref018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1590\/1516-3180.2016.011827016","article-title":"Association between asthma and female sex hormones","volume":"135","author":"RP Balda\u00e7ara","year":"2017","journal-title":"Sao Paulo Med J"},{"issue":"10","key":"pone.0257765.ref019","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/02770900802444187","article-title":"Sex differences in asthma","volume":"45","author":"JW McCallister","year":"2008","journal-title":"J Asthma"},{"issue":"10","key":"pone.0257765.ref020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11882-019-0878-y","article-title":"Novel Insights on Sex-Related Differences in Asthma","volume":"19","author":"P Zhang","year":"2019","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"pone.0257765.ref021","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0300-2896(15)32812-X","article-title":"GEMA4.0. Gu\u00eda espa\u00f1ola para el manejo del asma [GEMA(4.0). Guidelines for Asthma Management]","volume":"51","author":"V Plaza Moral","year":"2015","journal-title":"Arch Bronconeumol."},{"key":"pone.0257765.ref022","doi-asserted-by":"crossref","first-page":"212561","DOI":"10.7573\/dic.212561","article-title":"Severe refractory asthma: current treatment options and ongoing research","volume":"7","author":"F Menzella","year":"2018","journal-title":"Drugs Context"},{"key":"pone.0257765.ref023","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of Biologics in Asthma","volume":"199","author":"MC McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0257765.ref024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.anai.2019.07.012","article-title":"Choosing the right biologic for severe asthma: precision medicine through the lens of patient-centered decision making","volume":"123","author":"M Desai","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"pone.0257765.ref025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms Driving Gender Differences in Asthma","volume":"17","author":"H Fuseini","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"pone.0257765.ref026","doi-asserted-by":"crossref","first-page":"e1001333","DOI":"10.1371\/journal.pmed.1001333","article-title":"PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity","volume":"9","author":"PRISMA-Equity Bellagio group","year":"2012","journal-title":"PLoS Med."},{"key":"pone.0257765.ref027","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.medcli.2010.03.018","article-title":"Grupo de trabajo para el estudio de la inclusi\u00f3n de Mujeres en los Ensayos Cl\u00ednicos, y an\u00e1lisis de G\u00e9nero de los mismos. Recomendaciones para el estudio y evaluaci\u00f3n de las diferencias de g\u00e9nero en los ensayos cl\u00ednicos de f\u00e1rmacos en Espa\u00f1a [Recommendations for the study and evaluation of gender differences in clinical trials in Spain]","volume":"135","author":"E Chilet Rosell","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"pone.0257765.ref028","author":"European Commission","year":"2016","journal-title":"Research and Innovations, SWAFS. Gendered innovations. Sex and gender policies of major granting agencies"},{"key":"pone.0257765.ref029","author":"Government of Canada","year":"2013","journal-title":"Guidance Document: Considerations for Inclusion of Women in Clinical Trials and Analysis of Sex Differences"},{"key":"pone.0257765.ref030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1398-9995.2004.00533.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma","volume":"59","author":"JG Ayres","year":"2004","journal-title":"Allergy"},{"key":"pone.0257765.ref031","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"M Castro","year":"2014","journal-title":"Lancet Respir Med."},{"key":"pone.0257765.ref032","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ajem.2014.09.036","article-title":"A randomized trial of benralizumab, an antiinterleukin 5 receptor \u03b1 monoclonal antibody, after acute asthma","volume":"33","author":"RM Nowak","year":"2015","journal-title":"Am J Emerg Med."},{"key":"pone.0257765.ref033","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"ER Bleecker","year":"2016","journal-title":"Lancet"},{"key":"pone.0257765.ref034","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"JM FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"pone.0257765.ref035","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000444799","article-title":"A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan","volume":"169","author":"HS Park","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"pone.0257765.ref036","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","article-title":"Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"5","author":"GT Ferguson","year":"2017","journal-title":"Lancet Respir Med"},{"key":"pone.0257765.ref037","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma","volume":"376","author":"P Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref038","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial","volume":"11","author":"PL Zeitlin","year":"2018","journal-title":"J Asthma Allergy"},{"key":"pone.0257765.ref039","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JAA.S240044","article-title":"Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA)","volume":"13","author":"RA Panettieri","year":"2020","journal-title":"J Asthma Allergy"},{"key":"pone.0257765.ref040","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"S Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref041","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"S Wenzel","year":"2016","journal-title":"Lancet"},{"key":"pone.0257765.ref042","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"M Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref043","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma","volume":"378","author":"KF Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref044","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"P Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0257765.ref045","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"P Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref046","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"ID Pavord","year":"2012","journal-title":"Lancet"},{"key":"pone.0257765.ref047","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"EH Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref048","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"HG Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref049","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"W Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0257765.ref050","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"H Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"pone.0257765.ref051","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"M Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"key":"pone.0257765.ref052","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"ST Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"pone.0257765.ref053","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"AM Vignola","year":"2004","journal-title":"Allergy"},{"key":"pone.0257765.ref054","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"M Humbert","year":"2005","journal-title":"Allergy"},{"key":"pone.0257765.ref055","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"B Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0257765.ref056","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1843.2009.01633.x","article-title":"Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma","volume":"14","author":"1304 Study Group","year":"2009","journal-title":"Respirology"},{"key":"pone.0257765.ref057","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1398-9995.2010.02522.x","article-title":"Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma","volume":"66","author":"J Bousquet","year":"2011","journal-title":"Allergy"},{"key":"pone.0257765.ref058","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"for asthma in inner-city children","volume":"364","author":"WW Busse","year":"2011","journal-title":"N Engl J Med"},{"key":"pone.0257765.ref059","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"NA Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"pone.0257765.ref060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/02770903.2011.648296","article-title":"A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma","volume":"49","author":"J Bardelas","year":"2012","journal-title":"J Asthma"},{"key":"pone.0257765.ref061","first-page":"288","volume":"49","author":"QUALITX Study Investigators","year":"2012","journal-title":"Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX)J Asthma"},{"key":"pone.0257765.ref062","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"D Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0257765.ref063","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4168\/aair.2016.8.4.319","article-title":"Omalizumab Improves Quality of Life and Asthma Control in Chinese Patients With Moderate to Severe Asthma: A Randomized Phase III Study","volume":"8","author":"J Li","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"pone.0257765.ref064","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"M Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0257765.ref065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"M Castro","year":"2015","journal-title":"Lancet Respir Med."},{"key":"pone.0257765.ref066","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study","volume":"150","author":"L Bjermer","year":"2016","journal-title":"Chest"},{"key":"pone.0257765.ref067","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/ajrccm.162.1.9907008","article-title":"Differences in incidence of reported asthma related to age in men and women. A retrospective analysis of the data of the European Respiratory Health Survey","volume":"162","author":"R de Marco","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"pone.0257765.ref068","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0000000000000842","article-title":"A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies","volume":"71","author":"MJ Curno","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pone.0257765.ref069","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaci.2010.09.022","article-title":"Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study","volume":"127","author":"A Wijga","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0257765.ref070","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/S0091-6749(99)70258-7","article-title":"Interrelationships between asthma and pregnancy: a literature review","volume":"103","author":"M Schatz","year":"1999","journal-title":"J Allergy Clin Immunol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T18:19:09Z","timestamp":1632421149000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0257765"}},"subtitle":[],"editor":[{"given":"Stefanos","family":"Bonovas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0257765","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]}}}